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INTRODUCTION 
 
Tuberculosis, caused by mycobacterium tuberculosis is characterized by the  
presence of granulomas in the infected tissues. Tuberculosis is a disease of great 
antiquity. 
Tuberculosis lesions were seen in vertebrae of Neolithic man in Europe and in 
Egyptian mummies as early as 3700 B.C. although the lungs are commonly involved, 
it can involve any organ system in our body. Tuberculosis still continues to be a 
significant problem in the developing world and is on the rise in developed countries 
coinciding with increased incidence of HIV infection. 
 
          It is estimated that the 3 million people die from tuberculosis each year , the 
majority in developing countries.the annual incidence of new cases of all forms of 
tuberculosis (pulmonary and extrapulmonary ) world wide is estimated approximately 
8 million, of which 95% occur in developing countries. Consequently , the estimated 
prevalence worldwide is 16 to 20 millions of whom 8-10 million are sputum smear 
positive and highly infectious. 
 
        The number of persons infected with TB bacillus is estimated to be 6-7 billion , 
of  which 1.3 billion live in developing countries. In India , more than 40% of adults 
are infected with TB and approximately 1.5 million cases are put on treatment every 
year.   
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An estimated 5 lakh death from TB occur every year. The greatest burden of 
TB incidence and mortality in developing countries is in adults aged between 15 to 60 
years.  
Though haematological abnormalities associated with TB have been well 
recognised for nearly a century , not many comprehensive studies exist which describe 
the prevelance and relationship with the severity of the disease .Haematological 
changes have been observed with pulmonary, extrapulmonary and disseminated TB 
and usually reversible with ATT.  
 
        Anemia is common in TB. The extent of anemia depands on the extent of the 
disease; when TB is localized to only one organ  eg. Lung. The Hb level is usually 
normal until the disease has made considerable progress , when a mild to moderate 
normochromic normocytic or slightly hypochromic anemia may develop. Severe 
anemia is rare in the absence of complications of TB like disseminated TB, ulceration 
of bowel etc. 
 
Hb level is generally in the range of 1-3 gm/dl below the lower limit and 
normal for the age and sex of the patient.MCH is usually 22-26 pg. and MCV is 
usually 77-80 microlitre.slight to moderate anisocytosis and poikilocytosis may be 
present. Reticulocyte is not decreased . WBC count is usually not affected . rare 
associated with monoctosis and lymphocytosis. Platelets are usually normal or 
increased, but thrombocytopenia is per se very rare in pulmonary tuberculosis patients. 
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AIDS is a chronic, life-threatening condition caused by the human immunodeficiency  
virus (HIV). By damaging or destroying the cells of  immune system, HIV interferes with   
body's ability to effectively fight off viruses, bacteria and fungi that cause disease. This makes 
the people more susceptible to certain types of cancers and to opportunistic infections. The 
virus and the infection itself are known as HIV.  
The term acquired  immunodeficiency syndrome (AIDS) is used to mean the later 
stages of an HIV infection. 
               HIV infection is associated with numerous abnormalities of hematopoiesis, 
affecting both the myeloid and lymphoid lineages derived from the hematopoietic 
stem cell. Thus, as many as 70% to 80% of HIV-infected patients develop anemia 
during the course of infection, while neutropenia may be seen in more than 50% of 
individuals with more advanced HIV-related immunodeficiency. Thrombocytopenia is 
also common, occurring in approximately 40% of patients, and serving as the first 
symptom or sign of infection in approximately 10% of HIV-infected patients. 
 
HIV infection increases the risk of tuberculosis. The HIV epidemic is also 
likely to have an indirect effect on the incidence of tuberculosis because of the 
increased number of infectious individuals in the population.  
 
HIV infection has dramatically increased the incidence of tuberculosis. There 
was a direct increase in those who were HIV infected, but also a doubling in 
tuberculosis incidence in those remaining HIV negative, implying considerable 
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ongoing Mycobacterium tuberculosis transmission. This has occurred despite active 
case finding and directly observed therapy, which exceeds WHO targets for cure rates.  
 
In considering above facts , a comparative study was conducted in Government 
Rajaji Hospital , Madurai , to compare the haematological profile in patients with 
pulmonary tuberculosis per se and patients with pulmonary tuberculosis with HIV. 
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REVIEW OF LITERATURE 
 
Background:  
Tuberculosis (TB) is the number one infectious disease killer worldwide. The  
World Health Organization estimates that 2 billion people have latent TB, while 
another 3 million people worldwide die each year due to TB.  
ETIOLOGY:  
Pulmonary tuberculosis is caused by Mycobacterium tuberculosis. TB is 
transmitted by airborne droplet nuclei, which may contain fewer than 10 bacilli. 
Exposure to TB occurs by sharing common airspace with a patient who is infectious. 
When inhaled, droplet nuclei are deposited within the terminal airspaces of the lung. 
Upon encountering the bacilli, macrophages ingest and transport the bacteria to 
regional lymph nodes.  
The bacilli have 4 potential fates: (1) they may be killed by the immune 
system, (2) they may multiply and cause primary TB, (3) they may become dormant 
and remain asymptomatic, or (4) they may proliferate after a latency period 
(reactivation disease). Reactivation disease may occur following either (2) or (3) 
above.  
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BURDEN OF PULMONARY TUBERCULOSIS IN INDIA 
INDIA is in a unique position with respect to the  global tuberculosis epidemic. 
Tuberculosis remains the leading infectious cause of death in India, killing close to 
500,000 people a year. India has far more cases of tuberculosis than any other country 
in the world.-about 2 million new cases each year  and  accounts for nearly one third 
of prevalent cases globally. 
 
 
(REF 2 : Source WHO TB manual 2006) 
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( REF 4: Global incidence of tuberculosis between 1980-2005) 
 
World TB incidence. Cases per 100,000; Red = >300, orange = 200–300; yellow = 
100–200; green 50–100 and grey <50. Data from WHO, 2006. 
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Race: Tuberculosis is a worldwide infection. Endemic areas include India, Southeast 
Asia, and sub-Saharan Africa.  
Sex: No sex predilection exists for tuberculosis.  
Age: Infection may occur at any age and is most significant at the extremes of age. 
Primary tuberculosis is usually seen in young children in endemic regions. The 
incidence is increasing in individuals in nonendemic regions who are 
immunocompromised. 
PATHOLOGY AND PATHOGENESIS: 
About 90% of those infected with Mycobacterium tuberculosis have 
asymptomatic latent TB infection (sometimes called LTBI), with only a 10% lifetime 
chance that a latent infection will progress to TB disease. However, if untreated, the 
death rate for these active TB cases is more than 50%. 
            TB infection begins when the mycobacteria reach the pulmonary alveoli , 
where they invade and replicate within alveolar macrophages.  The primary site of 
infection in the lungs is called the Ghon focus . Bacteria are picked up by dendritic 
cells , which do not allow replication, although these cells can transport the bacilli to 
local (mediastinal) lymph nodes . Further spread is through the bloodstream to the 
more distant tissues and organs where secondary TB lesions can develop in lung 
apices, peripheral lymph nodes, kidneys, brain, and bone.All parts of the body can be 
affected by the disease, though it rarely affects the heart, skeletal muscles , pancreas 
and thyroid. 
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             Tuberculosis is classified as one of the granulomatous inflammatory 
conditions. Macrophages, T lymphocytes,  B lymphocytes  and fibroblasts  are among 
the cells that aggregate to form a granuloma  with lymphocytes  surrounding the 
infected macrophages.  
The granuloma functions not only to prevent dissemination of the 
mycobacteria, but also provides a local environment for communication of cells of the 
immune system. Within the granuloma, T lymphocytes (CD4+) secrete cytokines  
such as interferon gamma which activates macrophages to destroy the bacteria with 
which they are infected. T lymphocytes (CD8+) can also directly kill infected cells. 
             Importantly, bacteria are not always eliminated within the granuloma, but can  
become dormant, resulting in a latent infection. Another feature of the granulomas of 
human tuberculosis is the development of cell death, also called necrosis,  in the center 
of tubercles  To the naked eye this has the texture of soft white cheese and was termed 
caseous  necrosis. 
             If TB bacteria gain entry to the bloodstream from an area of damaged tissue 
they spread through the body and set up many foci of infection, all appearing as tiny 
white tubercles in the tissues. This severe form of TB disease is most common in 
infants and the elderly and is called miliary tuberculosis.  Patients with this 
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disseminated  TB have a fatality rate of approximately 20%, even with intensive 
treatment. 
         In many patients the infection waxes and wanes. Tissue destruction and necrosis  
are balanced by healing and fibrosis. Affected tissue is replaced by scarring and 
cavities filled with cheese-like white necrotic material. During active disease, some of 
these cavities are joined to the air passages bronchi and this material can be coughed 
up. It contains living bacteria and can therefore pass on infection. Treatment with 
appropriate antibiotics  kills bacteria and allows healing to take place. Upon cure, 
affected areas are eventually replaced by scar tissue. 
CLINICAL FEATURE  OF  TUBERCULOSIS : 
• Pulmonary tuberculosis (TB): Typical symptoms of pulmonary TB include a 
productive cough, fever, and weight loss. Occasionally, patients may present 
with hemoptysis or chest pain. Other systemic symptoms include anorexia, 
fatigue, or night sweats. 
• Tuberculous meningitis: Patients may present with a headache that is either 
intermittent or persistent for 2-3 weeks. Subtle mental status changes may 
progress to coma over a period of days to weeks. Fever may be low-grade or 
absent. 
• Skeletal TB: The most common site of involvement is the spine (Pott disease). 
Symptoms include back pain or stiffness. Lower extremity paralysis occurs in 
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as many as half the patients with undiagnosed Pott disease. Tuberculous 
arthritis usually involves only 1 joint. Although any joint may be involved, the 
hip or the knee is affected most commonly, followed by the ankle, elbow, 
wrist, and shoulder. Pain may precede radiographic changes by weeks to 
months. 
• Genitourinary TB: Reported symptoms include flank pain, dysuria, or 
frequency. In men, genital TB may manifest as epididymitis or a scrotal mass. 
In women, genital TB may mimic pelvic inflammatory disease. TB causes 
approximately 10% of sterility in women worldwide and approximately 1% in 
industrialized countries. 
• Gastrointestinal TB: Any site along the gastrointestinal tract may become 
infected. Symptoms are referable to the site infected, including the following: 
nonhealing ulcers of the mouth or anus; difficulty swallowing with esophageal 
disease; abdominal pain mimicking peptic ulcer disease with stomach or 
duodenal infection; malabsorption with infection of the small intestine; and 
pain, diarrhea, or hematochezia with infection of the colon. 
• Tuberculous lymphadenitis (scrofula): The most common site is in the neck 
along the sternocleidomastoid muscle. It usually is unilateral, with little or no 
pain. Advanced disease may suppurate and form a draining sinus. 
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• Cutaneous TB: Direct inoculation may result in an ulcer or wartlike lesion. 
Contiguous spread from an infected lymph node typically results in a draining 
sinus. Hematogenous spread may result in a reddish brown plaque on the face 
or extremities (lupus vulgaris) or tender nodules or abscesses. 
DIAGNOSIS OF TUBERCULOSIS : 
Microbiological studies 
A definitive diagnosis of tuberculosis can only be made by culturing 
Mycobacterium tuberculosis  organisms from a specimen taken from the patient (most  
often sputum , but may also include pus, CSF  biopsied tissue, etc.).  
Sputum smears and cultures  should be done for acid-fast bacilli if the patient 
is producing sputum. The preferred method for this is fluorescence microscopy  
(auramine-rhodamine staining), which is more sensitive than conventional Ziehl-
Neelsen staining. 
If no sputum is being produced, specimens can be obtained by inducing 
sputum, genital warts,  a laryngeal swab, bronchoscopy with bronchoalveolar lavage, 
or fine needle aspiration of a collection.  
Traditionally, cultures have used the  Löwenstein-Jensen (LJ), Kirchner, or 
Middlebrook media (7H9, 7H10, and 7H11).  
 Chest X-ray 
         In active pulmonary TB, infiltrates or consolidations and/or cavities are often 
seen in the upper lungs  with or without mediastinal or hilar lymphadenopathy or 
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pleural effusions ( tuberculous pleurisy). However, lesions may appear anywhere in 
the lungs. In disseminated TB a pattern of many tiny nodules throughout the lung 
fields is common – the so called milliary TB. In HIV and other immunosuppressed 
persons, any abnormality may indicate TB or the chest X-ray may even appear entirely 
normal. 
TUBERCULIN SKIN TEST 
Two tests are available: the Mantoux and Heaf tests. 
 Mantoux skin test 
 
Injecting a Mantoux skin test 
 
 
 
Reading mantoux after 48-72 hrs  
 
The Mantoux test for TB involves intradermally injecting PPD tuberculin and 
measuring the size of induration 48-72 hours later. 
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CDC classification of tuberculin reaction 
An induration (palpable raised hardened area of skin) of more than 5-15 mm 
(depending upon the person's risk factors) to 10 Mantoux units is considered a positive 
result, indicating TB infection. 
5 mm or more is positive in  
1. HIV-positive person  
2. Recent contacts of TB case  
3. Persons with nodular or fibrotic changes on CXR consistent with old healed 
TB  
4. Patients with organ transplants and other immunosuppressed patients  
10 mm or more is positive in 
1. 1.Recent arrivals (less than 5 years) from high-prevalent countries  
2. Injection drug users  
3. Residents and employees of high-risk congregate settings (e.g., prisons, 
nursing homes, hospitals, homeless shelters, etc.)  
4. Mycobacteriology lab personnel  
5. Persons with clinical conditions that place them at high risk (e.g., diabetes , 
prolonged corticosteroid therapy, leukemia , end-stage renal disease , chronic 
malabsorption  syndromes, low body weight, etc)  
6. Children less than 4 years of age, or children and adolescents exposed to adults 
in high-risk categories  
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15 mm or more is positive in  
1.Persons with no known risk factors for TB  
A tuberculin test conversion is defined as an increase of 10 mm or more within 
a 2-year period, regardless of age. 
 
RECENT TEST TO DETECT PULMONARY TB 
Adenosine deaminase 
In 2007, a systematic review of adenosine deaminase  by the NHS Health 
Technology Assessment Programme concluded "There is no evidence to support the 
use of ADA tests for the diagnosis of pulmonary TB. However, there is considerable 
evidence to support their use in pleural fluid samples for diagnosis of pleural TB, 
where sensitivity was very high, and to a slightly lesser extent for TB meningitis. In 
both pleural TB and TB meningitis, ADA tests had higher sensitivity than any other 
tests." 
Nucleic acid amplification tests (NAAT) 
This is a heterogeneous group of tests that use polymerase chain reaction 
(PCR) to detect mycobacterial nucleic acid. These test vary in which nucleic acid 
sequence they detect and vary in their accuracy. The two most common commercially 
available tests are the amplified mycobacterium tuberculosis direct test (MTD, Gen-
Probe) and Amplicor Interferon-γ release assays Interferon-γ (interferon-gamma) 
release assays (IGRAs) are based on the ability of the mycobacterium tuberculosis 
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antigens for early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10 
(CFP-10) to stimulate host production of interferon-gamma.  
Because these antigens are not present in non-tuberculous mycobacteria or in 
BCG vaccine, these tests can distinguish latent tuberculosis infection (LTBI). 
The blood tests QuantiFERON-TB Gold and T-SPOT.TB use these antigens to 
detect people with tuberculosis. Lymphocytes from the patient's blood are cultured 
with the antigens. These tests are called interferon γ tests and are not equivalent.If the 
patient has been exposed to tuberculosis before, T lymphocytes produce interferon γ in 
response.  
Both tests use ELISA  to detect the interferon γ with great sensitivity. The 
distinction between the tests is that QuantiFERON-TB Gold quantifies the total 
amount of interferon γ when whole blood is exposed to the antigens, whereas T-
SPOT.TB , a type of ELISPOT assay, counts the number of activated T lymphocytes 
that secrete interferon γ. 
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                                                            AIDS 
 
Acquired immune deficiency syndrome or acquired immunodeficiency 
syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from 
the specific damage to the immune system caused by the human immunodeficiency 
virus(HIV) in humans, and similar viruses in other species (SIV, FIV, etc.). The late 
stage of the condition leaves individuals susceptible to opportunistic infections and 
tumors. Although treatments for AIDS and HIV exist to decelerate the virus  
progression, there is currently no known cure.  
HIV, et al., are transmitted through direct contact of a mucous membrane or 
the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal 
fluid, preseminal fluid, and breast milk. This transmission can come in the form of 
anal, vaginal or oral sex, blood transfusion, contaminated hypodermic needles, 
exchange between mother and baby during pregnancy, childbirth, or breastfeeding, or 
other exposure to one of the above bodily fluids . 
HIV BURDEN IN  INDIA : 
Estimated number of people living with HIV/AIDS, 20063  
 People living with HIV/AIDS  2 million - 3.1 million 
 Adult (15 years or above) HIV prevalence  0.36% 
 
NACO (India 2006) 
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Previously it was thought that around 5 million people were living with HIV in 
India - more than in any other country. Better data, including the results of a national 
household survey, led to a major revision of the prevalence estimate in July 2007. It is 
now thought that around 2.5 million people in India are living with HIV. 
EPIDEMOLOGY OF HIV BURDEN : 
 
Prevalence of HIV among adults per country at the end of 2005. 
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Age distribution of HIV infected patients in INDIA ( 2007) 
HIV prevalence (%) 
Age group 
Male Female Total 
15-19 0.01 0.07 0.04 
20-24 0.19 0.17 0.18 
25-29 0.43 0.28 0.35 
30-34 0.64 0.45 0.54 
35-39 0.53 0.23 0.37 
40-44 0.41 0.19 0.30 
45-49 0.48 0.17 0.33 
Total age 15-49 0.36 0.22 0.28 
 
The National Family Health Survey, which tested more than 100,000 people 
for HIV, also found prevalence to be higher in urban areas (0.35%) than in rural areas 
(0.25%). 
Sex distribution of HIV patients in INDIA (2007 ) 
Gender Cumulative AIDS cases 
Male 88,245 
Female 36,750 
Total 124,995 
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HIV BURDEN IN TAMIL NADU : 
When surveillance systems in the southern Indian state of Tamil Nadu, home 
to some 62 million people, showed that HIV infection rates among pregnant women 
were rising - tripling to 1.25% between 1995 and 1997 - the State Government acted 
decisively. Funding for the Tamil Nadu State AIDS Control Society (TANSACS), 
which had been set up in 1994, was significantly increased. Along with non-
governmental organisations and other partners, TANSACS developed an active AIDS 
prevention campaign. This included hiring a leading international advertising agency 
to promote condom use for risky sex in a humorous way, without offending the many 
people who do not engage in risky behaviour. The campaign also attacked the 
ignorance and stigma associated with HIV infection.   
The HIV prevalence at antenatal clinics in Tamil Nadu was 0.88% in 2002 and 
0.5% in 2005, though several districts still have rates above 1%. The general 
population survey of 2005-2006 found a rate of 0.34% across the state. Prevalence 
among injecting drug users was 18% in 2005. Tamil Nadu had reported 52,036 AIDS 
cases to NACO by July 2005, which is by far the highest number of any state. 
 
PATHOGENESIS OF HIV INFECTION : 
        AIDS is the most severe acceleration of infection  with HIV. HIV is a retrovirus 
that  primarily infects vital organs of the human immune system such as CD4+ T cells 
(a subset of T cells , macrophages  and dendritic cells. It directly and indirectly 
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destroys CD4+ T cells. CD4+ T cells are required for the proper functioning of the 
immune system.  
When HIV kills CD4+ T cells so that there are fewer than 200 CD4+ T cells per 
microliter  (µL) of blood , cellular immunity is lost, leading to the condition known as 
AIDS. Acute HIV infection progresses over time to clinical latent HIV infection and 
then to early symptomatic HIV infection and later to AIDS, which is identified on the 
basis of the amount of CD4+ T cells in the blood and the presence of certain infections. 
            In the absence of antiretroviral therapy , the median time of progression from 
HIV infection to AIDS is nine to ten years, and the median survival time after 
developing AIDS is only 9.2 months. However, the rate of clinical disease progression 
varies widely between individuals, from two weeks  up to 20 years. Many factors 
affect the rate of progression. These include factors that influence the body's ability to 
defend against HIV such as the infected person's general immune function. Older 
people have weaker immune systems, and therefore have a greater risk of rapid 
disease progression than younger people. Poor access to health care  and the existence 
of coexisting infections such as tuberculosis  also may predispose people to faster 
disease progression. The infected person's genetic inheritance plays an important role 
and some people are resistant  to certain strains of HIV. An example of this is people 
with the CCR5-∆32 mutation are resistant to infection with certain strains of HIV.HIV 
is genetically variable and exists as different strains, which cause different rates of 
clinical disease progression.  
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The use of highly active antiretroviral therapy prolongs both the median time 
of progression to AIDS and the median survival time. 
DIAGNOSIS : 
WHO disease staging system for HIV infection and disease 
In 1990, the World Health Organization (WHO) grouped these infections and 
conditions together by introducing a staging system for patients infected with HIV-1. 
An update took place in September 2005. Most of these conditions are opportunistic  
infections that are easily treatable in healthy people. 
Stage I:  HIV infection is asymptomatic and not categorized as AIDS  
Stage II:  includes minor mucocutaneous manifestations and recurrent upper 
respiratory tract infections  
Stage III:  includes unexplained chronic diarrhea for longer than a month, severe 
bacterial infections and pulmonary tuberculosis  
Stage IV:  includes toxoplasmosis of the brain, candidiasis of the esophagus, 
trachea, bronchi or lungs and Kaposi's sarcoma, these diseases are 
indicators of AIDS. 
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A generalized graph of the relationship between HIV copies (viral load) 
and CD4 counts over the average course of untreated HIV infection. 
(Blue line)CD4+ T Lymphocyte count (cells/mm³) 
(Black line) HIV RNA copies. 
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HIV AND TB 
 
Tuberculosis and HIV around the world 
Tuberculosis is the most common HIV-related opportunistic infection in India, 
and caring for patients with both diseases is a major public health challenge. India has 
about 1.8 million new cases of tuberculosis annually, accounting for a fifth of new 
cases in the world — a greater number than in any other country .  Patients with latent 
Mycobacterium tuberculosis infection are at higher risk for progression if they are 
coinfected  with HIV. Patients with HIV infection have a similar bacteriologic 
response to tuberculosis treatment as those who are not infected but have higher risks 
of recurrence and death. The influence of tuberculosis coinfection on the progression 
of HIV disease is controversial. 
In 2004, about 330,000 people in India died from tuberculosis.1 Two of every 
five persons — more than 400 million — have latent tuberculosis infection.3 
Tuberculosis can be expected to develop in more than half of those who are also 
infected with HIV. At present, however, only about 5% of new tuberculosis cases in 
India occur in people with HIV coinfection. The situation differs from that in sub-
Saharan Africa, where the incidence of tuberculosis in many countries is higher than in 
India and as many as 80% of patients with tuberculosis are coinfected with HIV. In 
Africa, HIV has reversed gains in tuberculosis control that were achieved a quarter-
century ago.Such a reversal is unlikely to occur in India. 
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People with latent TB are increasingly becoming infected with HIV, and many 
more are developing active TB because HIV is weakening their immune system. 
People who are co-infected with both HIV and latent TB have an up to 800 times 
greater risk of developing active TB disease and becoming infectious compared to 
people not infected with HIV.  
People with advanced HIV infection are vulnerable to a wide range of 
infections and malignancies that are called 'opportunistic infections  because they take 
advantage of the opportunity offered by a weakened immune system. Tuberculosis is 
an HIV related opportunistic infection. A person that has both HIV and active TB has 
an AIDS-defining illness.  
The HIV/AIDS epidemic is reviving an old problem in well resourced 
countries and greatly worsening an existing problem in resource poor countries. The 
are several important associations between epidemics of HIV and tuberculosis:  
1. Tuberculosis is harder to diagnose in HIV positive people 
2. Tuberculosis progresses faster in HIV-infected people  
3. Tuberculosis in HIV positive people is more likely to be fatal if 
undiagnosed  or left untreated  
4. Tuberculosis occurs earlier in the course of HIV infection than other  
opportunistic infections  
5. Tuberculosis is the only major AIDS-related opportunistic infection 
that poses a risk to HIV-negative people. 
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PATHOGENESIS OF HIV & TB COINFECTION 
    
CD4 cell-mediated immunity and macrophage function are essential in the 
control of M tuberculosis infection. During primary infection of an immunocompetent 
host, cell-mediated immunity usually develops and arrests progression of disease. 
About 5% of patients whose primary infection is controlled have reactivation years to 
decades later. In another 5% of patients, infection is not contained, and primary 
pulmonary, extrapulmonary, or disseminated TB can occur.  
The hallmark of HIV infection is progressive deterioration and depletion of 
CD4 cells, coupled with defects in macrophage and monocyte function. There is 
evidence that the immune response in patients with TB might enhance HIV viral 
replication and accelerate the natural progression of HIV infection. The risk of TB 
developing in an HIV-infected patient who is latently coinfected with M tuberculosis 
approaches 10% per year, as opposed to a 10% lifetime risk in an immunocompetent 
host. Patients with more advanced HIV infection (CD4 count, <200 cells/mm3) who 
are newly infected with M.tuberculosis may lack the ability to contain the primary 
infection, which can progress rapidly and is fatal if not treated.  
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HAEMATOLOGICAL MANIFESTATIONS OF 
TUBERCULOSIS 
 
Anaemia is a common complication of pulmonary tuberculosis. The precise 
mechanism of anaemia in pulmonary tuberculosis is not clearly known, but anaemia of 
inflammation as well as of Fe deficiency has been implicated. Both are common in 
developing countries. It is extremely difficult to distinguish anaemia of Fe deficiency 
from anaemia of inflammation with the haematological indices used routinely. Adult 
male patients 15-60 years of age with pulmonary tuberculosis and a blood 
haemoglobin concentration 80-110 g/l were included in the study; healthy adult males 
matched for age and socio-economic status were taken as controls. Blood 
haemoglobin concentration, total erythrocyte count (TEC), packed cell volume (PCV), 
mean corpuscular volume (MCV), mean corpuscul ar haemoglobin and serum Fe, total 
Fe-binding capacity and ferritin were estimated before treatment and 1, 2 and 6 
months after treatment. ( REF 7 ) 
 
Reactive thrombocytosis in pulmonary tuberculosis ( ref 12 ) 
The incidence of reactive thrombocytosis in active pulmonary tuberculosis was 
studied in 122 patients. Thrombocytosis was common, platelet counts often exceeding 
1 X 10(12)/1.  
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A significant inverse correlation was noted between the mean platelet volume 
and the platelet count (r = -0.54, p less than 0.0001). Interval estimation suggested that 
this relation was non-linear. Further studies were done in a small group of six patients.  
Platelet survival was considerably shortened, the platelets aggregated 
excessively in vitro, serum concentrations of thrombopoiesis stimulating activity were 
raised, and serotonin uptake and release were within normal limits. The degree of 
thrombocytosis correlated significantly with the degree of inflammation measured by 
the erythrocyte sedimentation rate (r = 0.40, p less than 0.003) and serum C-reactive 
protein concentration (r = 0.35, p less than 0.008). 
 
HAEMATOLOGICAL MANIFESTATION IN HIV 
PATIENTS 
 
HIV infection is associated with numerous abnormalities of hematopoiesis, 
affecting both the myeloid and lymphoid lineages derived from the hematopoietic 
stem cell. Thus, as many as 70% to 80% of HIV-infected patients develop anemia 
during the course of infection, while neutropenia may be seen in more than 50% of 
individuals with more advanced HIV-related immunodeficiency. Thrombocytopenia is 
also common, occurring in approximately 40% of patients, and serving as the first 
symptom or sign of infection in approximately 10% of HIV-infected patients. (ref 13)  
Anemia is very common in HIV-infected individuals, occurring in 
approximately 30% during the initial asymptomatic years of infection and found in 
80% to 90% of patients over the course of disease. In an attempt to ascertain the 
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precise incidence of anemia in the setting of HIV infection prior to the availability of 
HAART, Sullivan and colleagues evaluated data derived from the case records of 
32,867 HIV-infected persons who received medical care from January 1990 through 
August 1996.. Using a definition of anemia as a hemoglobin level < 10 g/dL or a 
physician's diagnosis of anemia, the authors calculated the 1-year incidence of anemia 
as a function of the stage of HIV disease. The 1-year incidence of anemia was 37% 
among patients with clinical AIDS, 12% among patients with immunologic AIDS, as 
defined by a CD4+ cell count < 200 cells/mm3 in the absence of an AIDS-defining 
clinical condition; and 3% among HIV-infected individuals with neither clinical nor 
immunologic AIDS. ( REF 14 )  
Neutropenia is reported in approximately 10% of patients with early, 
asymptomatic HIV infection, and in more than 50% of those individuals with more 
advanced HIV-related immunodeficiency. As with other peripheral blood cytopenias 
in the setting of HIV infection, multiple etiologies for neutropenia may be present, 
either singly or in combination. Thus, decreased colony growth of the committed 
progenitor cell, CFU-GM, may lead to decreased production of both granulocytes and 
monocytes. Soluble inhibitory substances, produced by HIV-infected cells, have been 
noted to suppress neutrophil production in vitro. Decreased serum levels of G-CSF 
have been described in HIV-seropositive subjects with afebrile neutropenia (< 1000 
neutrophils/dL), indicating that a relative deficiency of this specific hematopoietic 
growth factor may also contribute to persistent neutropenia.  
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Finally, myelosuppression and neutropenia may result from any one of several 
medications commonly used in HIV-infected patients. ( ref 15 )  
Thrombocytopenia is relatively common during the course of HIV infection, 
occurring in approximately 40% of patients and serving as the first symptom or sign of 
infection in approximately 10%. Sullivan and colleagues recently evaluated the 1-year 
incidence of thrombocytopenia (< 50,000/mm3) in a group of 30,214 HIV-infected 
patients as part of the retrospective 10-city Adult and Adolescent Spectrum of Disease 
Project, sponsored by the CDC. The incidence of thrombocytopenia during 1 year was 
8.7% in patients with clinical AIDS, 3.1% in patients with immunologic AIDS (CD4+ 
cell count < 200 cells/mm3), and 1.7% in patients with neither condition. Over time, 
development of thrombocytopenia was associated with clinical or immunologic AIDS, 
history of injection drug use, history of anemia or lymphoma, and African American 
race. After controlling for multiple factors (AIDS, CD4+ cell count, anemia, 
neutropenia, antiviral therapy, receipt of prophylaxis against P carinii), 
thrombocytopenia was significantly associated with shorter survival (risk ratio, 1.7: 
95% confidence interval = 1.6-1.8).  
The major cause of thrombocytopenia in HIV disease is idiopathic 
thrombocytopenic purpura (ITP), in which antibody-coated platelets are removed from 
the circulation by the macrophages in the spleen. The resulting thrombocytopenia may 
result in bleeding or bruising, predominantly from the mucous membranes or skin. 
However, the majority of patients with HIV-related ITP do not actually experience 
bleeding or have had only minor bleeding manifestations. Furthermore, the likelihood 
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of clinical bleeding is very low until the platelet count drops below 10,000/mm3. 
Nonetheless, the potential risk of life-threatening bleeding into the central nervous 
system does exist in the setting of ITP, serving to render this a condition of some 
concern. ( ref 15 ) 
 
HAEMATOLOGICAL MANIFESTATIONS IN HIV – TB 
                             INFECTED PATIENTS 
 
¾ Isolated thrombocytopenia commonly seen in these patients. 
¾ Severe degree of anemia , leucopenia , pancytopenia seen in advanced disease . 
¾ Severe cytopenia is also secondary to myelosuppressive drug therapy or 
hypersplenism. 
¾ Leucocytosis is more common in patients with extra-pulmonary tuberculosis 
with out HIV than patient with HIV infection. ( ref 16 ) 
 
According to this study absolute lymphocyte count of less than 1x 10 – 9 / litre 
in  80% of HIV – TB patients and in only 40 % of HIV NEGATIVE  - TB POSITIVE 
patients. ( ref 17). 
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AIM OF THE STUDY 
 
       
1.  To study selected Haematological  parameters  namely 
haemoglobin, Total RBC count, WBC count, ESR, and platelets in  
pulmonary tuberculosis patients. 
 
      2.   To find out variations among HIV positive and negative patients.   
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MATERIALS AND METHOD 
 
Setting  : All TB patients who were attending Thoracic medicine department , GRH, 
Madurai. And patients refered from Anti retroviral therpy centre, with sputum 
positivity for AFB ( acid fast bacillius ) 
 
Collaborating Departments : Department of thoracic medicine & 
                                                         Anti retroviral therapy centre (ART )  
                                      Madurai Medical College 
     Madurai.  
        
Design of the study     :  ANALYTICAL STUDY  
Period of study     : 01.09.2006 – 31.10.2007 
Sample size        : 60 
                                                          ( TB with HIV : 30 / TB without HIV : 30 ) 
Ethical committee approval : Obtained  
Consent    : Informed consent was obtained  
Financial support    : Nil  
Conflict of interest    :  Nil  
A total of sixty cases were taken for  the study. They were divided in to two 
groups. The first group was sputum smear positive pulmonary tuberculosis ,which 
consist of thirty patients and they were HIV ELISA negative . the second group was 
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sputum smear positive pulmonary tuberculosis , which consist of thirty and they were 
HIV ELISA positive. 
 
BASELINE INVESTIGATIONS : 
A  baseline  blood glucose ( random blood sample) ,renal function test ( blood 
urea and serum creatinine), liver function test ( total / direct / indirect bilirubin , 
SGOT, SGPT , ALP ) , total protein , albumin , globulin. was done in all sixty 
patients.  
SELECTION CRITERIA: 
In the pulmonary tuberculosis group, only sputum positive for acid fast bacilli 
were selected for this study . Then according to the ELISA positivity they were 
divided in to TB + VE  HIV negative and TB + VE HIV positive. 
A total of sixty patients were taken for this study. The patients selected were 
more than 15 years of age group. Among HIV negative  and TB positive : twenty three 
were males and seven were females. Among HIV positive and TB positive : twenty 
four were males and six were females.  
All patients taken the study had active disease. In HIV + ve patients CD4+ 
cells count in range between 200-350 cells/microlitre and HIV RNA copies less than  
50,000/ml were selected for this study. 
EXCLUSION CRITERIA : 
1. old healed pulmonary tuberculosis lesion. 
2. diabetes and other metabolic disorder. 
3. malignancy 
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4. collagen vascular disorder 
5. gross organ disorder. 
6. patients on steroid, iron therpy ,or vitamin therpy. 
7. patients with bleeding disorder. 
8. Tobacco and alcoholics. 
9. pregnancy 
10. past and current intake of ATT (anti tuberculosis therapy ) 
11. patients on ART ( anti retroviral therapy ) . 
12. CD4+ < 200 cells / microlitre and HIV RNA copies > 1,00,000 / ml.  
 
Tuberculosis patients were diagnosed by clinical examination, X-ray chest ( 
PA view) and sputum smear examination. The sputum smear examination was done 
by Ziehl- Neelson technique. Sputum specimen was collected on the spot when a 
patient is suspected to of having tuberculosis. This is called a spot specimen. The 
patient is then given a sputum container to collect an early morning specimen before 
his second meeting . this is called early morning specimen. When the patient returns 
with the early morning specimen, a second spot specimen is also collected. 
The  ZIEHL – NEELSON staining : 
1. spread the sputum on a slide using a broom-stick. 
2. Allow the slide to air dry for 15 – 30 minutes. 
3. Fix the slide by passing it over a flame 3 – 5 times for 3 – 4 seconds each time. 
4. Pour filtered Carbol-fuschin to cover the entire slide. 
5. Gently heat the the slide until vapour rise . do not boil. 
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6. Leave it for 5 minutes. 
7. Gently rinse the slide with tap water until all the carbol fuschin stain is washed        
away.  
8. Pour 25% sulphuric acid on to the slide . 
9. Wait for 2 – 4 minutes. 
10. Rinse gently with tap water and allow it to drain off. 
11. If the slide is still red , re apply sulphuric acid for 1-3 minutes and rinse with 
tap water.   
12.  Pour 0.1 % methylene blue on to the slide and wait for 30 seconds. 
13. Rinse with tap water and allow it to dry. 
14. Examine the slide under microscope using X 40 lens to select the suitable area  
       and then examine , under X 100 lens using a drop of immersion oil.     
           
Confirmation of HIV infection is by ELISA antibody testing.  It was 
reconfirmed  using WESTERN BLOT technique. The method of ELISA used in this 
technique is INDIRECT ELISA TECHNIQUE. 
Patients height was measured in metre and weight was measured in kilograms . 
then by using the formula Height /(Weight)2 the BMI was calculated .  
A full blood blood count was carried out in a 5ml anticoagulated  blood 
sample. A thick and thin stained blood film was prepared for examination of 
morphology of the different cells and by specific stains red blood cell , white blood 
cell and platelet count was determined. 
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The examination of stained blood film is most important and by this the red 
cells are examined to access their degree of haemoglobinisation and their shape. If 
both are normal , they are called as normochromic and normocytic . pale staining 
which suggests under haemoglobinisation is called as hypochromia and reduction in 
the size of RBC is called  as microcytosis. 
One ml of blood is introduced in to automated cell counter. Specific values like 
Haemoglobin, RBC count , WBC ( total ) count , Differential count (D.C) , Platelet 
count ,  are obtained which are the basic parameters to be studied. 
Cell counters 
Automated cell counters sample the blood, and quantify, classify, and describe 
cell populations using both electrical and optical techniques. Electrical analysis 
involves passing a dilute solution of the blood through an aperture across which an 
electrical current is flowing. The passage of cells through the current changes the 
impedance between the terminals (the Coulter principle.A lytic reagent is added to the 
blood solution to selectively lyse the red cells (RBCs), leaving only white cells 
(WBCs), and platelets intact. Then the solution is passed through a second detector. 
This allows the counts of RBCs, WBCs, and platelets to be obtained. The platelet 
count is easily separated from the WBC count by the smaller impedance spikes they 
produce in the detector due to their lower cell volumes. 
Optical detection may be utilised to gain a differential count of the populations 
of white cell types. A dilute suspension of cells is passed through a flow cell, which 
passes cells one at a time through a capillary tube past a laser beam. The reflectance, 
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transmission and scattering of light from each cell is analysed by sophisticated 
software giving a numerical representation of the likely overall distribution of cell 
populations. 
ESR : 
ESR is calculated in both HIV +VE TB NEGATIVE and HIV +VE TB 
POSITIVE patients. To perform the test, anticoagulated blood  is placed in an upright 
tube, known as a Westergren tube and the rate at which the red blood cells  fall is 
measured and reported in mm/h. 
The normal values are ;  
MEN  
< 50 years - <15mm/hr and 
 > 50 years - <20 mm/hr. 
WOMEN  
< 50 years - < 20 mm/hr and  
> 50 years - < 30 mm/hr. 
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RESULTS 
 
The collected data was analysed using Epidemiological information package 
2002 developed by Centre for Disease Control (CDC) Atlanta in Collaboration with 
WHO. CHI square test was used for test of significance. These data was compared 
with published literature. 
 
In our there were 60 patients and they were divided in to two broad categories , 
namely TB with HIV patients and TB without HIV. 
 
 
CHARECTERISTICS OF CASES INCLUDED IN THE STUDY : 
 
STATUS OF THE PATIENTS NUMBER OF PATIENTS 
TB with HIV 30 
TB without HIV 30 
 
 
 
 
 46
 AGE AND SEX DISTRIBUTION ; 
TABLE: 1 
 
Status MALES % FEMALES % 
TB with HIV 25 83.3 5 16.6 
TB without HIV 23 76.6 7 23.3 
 
Regarding distribution of sex , there is a male predominance in the study. 
Around  83.3%  are males among TB with HIV group and females are only 16.6% in 
this group. In case of TB without HIV also male dominated this study around 76.6% 
and only 23.3% females.[table 1 ] 
TABLE: 2 
 
 < 25 yrs % 25 – 45 yrs % > 45 yrs % 
TB with HIV 1 3.3 21 70 8 26.6 
TB without HIV 0 0 26 86.6 4 13.3 
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TABLE: 3 
                        
<25 years 25 – 45 years > 45 years  
males females males females males females
TB with HIV 0 1 17 4 8 0 
TB without HIV 0 0 21 5 2 2 
 
 
Both TB and HIV affects mainly the adult age group. In our study around 70% 
of patients belonging to TB with HIV were in age group of 25 – 45 years. Among 
patients belonging to TB without HIV also predominantly belong to this age group 
which constitute around 86.6%. 
 Among 70% of patients belonging to TB with HIV , 56.6% were males and 
13.3% were females. Likewise , among 86.6% of patients belonging to TB without 
HIV group , 70% were males and 16.6% were females.[table 2,3 ] 
 
BODY MASS INDEX : 
Since both TB and HIV are chronic wasting disease , the co-infection of TB 
with HIV further worsen this scenario. From this study, 90% of patients belonging TB 
with HIV were underweight with BMI less than 18.5. 
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Among the patients belonging to TB without HIV  73.3 % were under the 
category of underweight with their BMI less than 18.5. only 2 patients belonging to 
TB without HIV were under the category of overweight with their BMI more than 
24.9. 
There were no patients under TB with HIV with BMI more than 24.9%.       
[table 4 ] 
 
TABLE: 4 
 
< 18.5 18.5 – 24.9 > 24.9  
n % n % n % 
TB with HIV 27 90 3 10 0 0 
TB without HIV 22 73.3 6 20 2 6.6 
 
BMI                 
<18.5Æunderweight 
18.5-24.9Ænormal 
>24.9Æoverweight 
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CORELATION OF HAEMATOLOGICAL PARAMETERS 
WITH THE STUDY GROUPS : 
HAEMOGLOBIN 
 
TABLE: 5 
 
< 11 gm / dl > 11 gm / dl  
n % n % 
TB with HIV 24 80 6 20 
TB without HIV 20 66.6 10 33.3 
 
From the table 5 ,  Anemia is common in both and 80% of anemic patients in 
TB with HIV , 70% were males and 10 % were females. Among 66.6% of anemic 
patients in TB without HIV group, 50% were males and 16.6% were females. 
Association of HIV with TB further worsens the anemia, as evidenced by 
33.3% of TB without HIV were not anemic , whereas only 20% of the patients in TB 
with HIV were not anemic. 
With respect to sex distribution among anemic patients in both groups , males 
were more affected, with 70% in TB with HIV and 50% in TB with out HIV.[table 6 ] 
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TABLE: 6 
< 11 gm / dl > 11 gm / dl  
males females males females 
TB with HIV 21 70% 3 10 % 4 13.3 % 2 6.6% 
TB without HIV 15 50% 5 16.6% 8 26.6% 2 6.6% 
 
TABLE: 7 
 RANGE MEDIAN MEAN 
TB WITH HIV 6.4 – 12.6 Gm 9.1 Gm 9.2 Gm 
TB WITHOUT HIV 6.0 – 12.8 GM 9.9 Gm 9.74 Gm 
 
 
RED BLOOD CELLS : 
In correlation with haemoglobin, total RBC counts were reduced in both the 
study groups, 80% of the patients belonging to TB with HIV had counts less than 3.5 
million cell/cumm. 
Whereas 83.3% of patients in TB without HIV group had counts less than the 
reference range. [table 8, 9 ] 
 
REFERENCE RANGE FOR TOTAL RBC COUNT : 3.8 – 5.8 million 
cells/cumm. 
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TABLE: 8 
 
RBC RANGE 
(millions/cumm)
MEDIAN 
(millions/cumm) 
MEAN 
(millions/cumm) 
TB with HIV 2.3 – 4.2 3.3 3.3 
TB without HIV 2.2 -  4.2 3.0 3.1 
 
TABLE: 9 
 
< 3.8 million RBC / cumm 3.8-5.8 million RBC / cumm  
males females males females 
TB with HIV 21 70% 3 10% 4 13.3% 2 6.6%
TB without HIV 20 66.6% 5 16.6% 3 10% 2 6.6%
 
 
WHITE BLOOD CELL ( WBC ) COUNT / TOTAL COUNT : 
There is no much difference in total WBC count among two study groups. 
From tables 10 and 11 , we can infer that 28 patients in TB with HIV and 28 patients 
in TB without HIV have their total counts with in the normal range of 3,500 – 10 ,000 
cells / cumm. 
Only 2 patients in TB with HIV had lecopenia and none had leucocytosis. 
Whereas 2 patients in TB without HIV had leucocytosis and none had 
leucopenia. 
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TABLE: 10 
 
WBC 
(in cells /cu mm ) 
RANGE MEDIAN MEAN 
TB WITH HIV   3400 - 10000          6500          6538 
TB WITHOUT HIV   3600 - 10950          6500         6696 
  
 
TABLEL 11 
< 3,500 cells / 
cumm 
3,500-10,000 cells / 
cumm 
> 10,000 cells /  
cumm 
 
males females males females males females
TB with HIV 2 0 23 5 0 0 
TB without HIV 0 0 22 6 1 1 
   
 
DIFFERENTIAL COUNT ( D.C ) 
There was no much difference in neutrophil and lymphocyte counts among 
these two study groups. Among the 30 patients in TB with HIV 76.6% of males and 
16.6% of females had normal range of neutrophil counts ( NORMAL RANGE: 43 – 
76 %), 
Whereas 70% were males and 23.3% were females among TB without HIV. 
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PLATELETS: 
TABLE: 12 
PLATELETS 
(in cells / cu mm ) 
RANGE MEDIAN MEAN 
TB WITH HIV 40,000 – 3,00,000 1,60,000 1,54,333 
TB WITHOUT HIV 1,00,000 – 5,60,000 3,05,000 3,31,666 
 
From tables 12 and 13, we can infer that thrombocytopenia is major finding 
among TB with HIV patients. Around 63.3% patients have thrombocytopenia and 
36.6% patients had normal platelet count among TB with HIV group. 
Whereas thrombocytopenia was only 10% among TB without HIV patients. 
Instead 53.3% patients had normal platelet counts and around 36.6% patients had 
thrombocytosis. 
TABLE: 13 
<1,50,000 
cells/cumm 
1,50,000-3,90,000 
cells/cumm 
>3,90,000 
cells/cumm 
 
n % n % n % 
TB with HIV 19 63.3 11 36.6 0 0 
TB without HIV 3 10 16 53.3 11 36.6 
 
    . 
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TABLE: 14 
<1.5 lacs/cu mm 1.5-3.9 lacs/cu mm >3.9 lacs / cu mm 
 
males females males females males females 
TB with HIV 16 53.3% 3 10% 9 30% 2 6.6% 0 0 0 0 
TB without 
HIV 
3 10% 0 0 12 40% 4 13.3% 8 26.6% 3 10% 
 
From table 14 we can infer that , among the thrombocytopenic patients in TB 
with HIV , 53.3% were males and 10% were females. And among the patients with 
thrombopoesis in TB without HIV , 26.6% were males and 10% were females. 
The  p value is 0.0001, hence this correlation of platelet count among these 
two study group is significant. 
 
ERYTHROCYTE  SEDIMENTATION RATE: 
TABLE: 15 
ESR 
(IN  MM / HR ) 
RANGE MEDIAN MEAN 
TB WITH HIV          20 - 120             98           102 
TB WITHOUT HIV          60 - 120             30            38  
 
  From table 15 , we can infer that, the range of ESR among patients with TB 
and HIV was 20 – 102 , whereas it was between 60 – 120 among TB patients without 
HIV . 
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Similarly the mean ESR was 38 mm / hr among TB with HIV patients, 
whereas it is 102 mm /hr among TB patients without HIV. 
 
TABLE: 16 
 
0 – 30 mm / hr 31 – 60 mm / hr 61 – 90 mm / hr 91 – 120 mm / hr  
n % n % n % n % 
TB with HIV 16 53.3 9 30 2 6.6 3 10 
TB without HIV 0 0 1 3.3 16 53.3 13 43.3 
 
TABLE: 17 
 
0-30mm/hr 31-60mm/hr 61-90mm/hr 91-120mm/hr  
males females males females males females males females
H+ 13 43% 2 10% 7 23% 2 7% 2 7% 0 0 3 10% 0 0 
H- 0 0 0 0 1 3% 0 0 13 43% 3 10% 9 30% 4 13%
 
From tables 16 and 17 , we can infer that , most patients have their ESR < 60 
mm / hr i.e around 83.3% patients among TB with HIV study group. Whereas around 
96.6 % patients have their ESR around 60 – 120 mm / hr among TB without HIV. 
The P value is 0.002, which is significant. 
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DISCUSSION & COMPARATIVE ANALYSIS 
 
This study comprises two sets of study groups. First group of patients consist 
of pulmonary tuberculosis patients with asymptomatic HIV infection. Second group of 
patients consist of pulmonary tuberculosis per se. 
Thirty patients were chosen randomly in each group to avoid selection bias. 
Patients less than 15 years and more than 60 years were excluded . After excluding the 
patients coming under exclusion criteria ( REF table 2 page :   ) , thirty patients were 
chosen in each category. 
Among tuberculosis patients, only pulmonary tuberculosis patients were 
included in this study , excluding extra – pulmonary tuberculosis , Multi – Drug 
resistant TB ( MDR TB ) , disseminated TB. 
The diagnosis of pulmonary TB was made after routine clinical examination, 
which include cough with expectoration for more than three weeks , evening rise of 
temperature , anorexia , loss of weight. Such patients were subjected to three days 
sputum analysis. Patients with sputum AFB positivity were alone chosen for this 
study. 
These sputum positivity patients were further subjected to clinical 
examination. 
Those patients who gave sexual promiscuity and high risk group for sexually 
transmitted diseases were further subjected to HIV screening test after written consent. 
 57
The high risk group patients belong to commercial sex workers , lorry / truck 
drivers , multiple sex partners , child abuse , ex – prisoners , etc. 
Those patients with HIV ELISA test positivity were isolated , and HIV was 
further confirmed using the gold standard test namely WESTERN BLOT. 
These TB patients with HIV positivity were subjected to CD 4 + cells count 
assay and HIV RNA copies were measured. Those patients with CD 4 + cell count 
between 200 – 350 and HIV RNA copies between <1,00,000 were only chosen for this 
study. 
Hence the HIV patients chosen for this study were mostly  asymptomatic or in 
the early stage of HIV infection. 
Clinically some of these patients had oral candidasis in our study group 14 
patients had oral candidasis. But for that, they had only symptoms and signs of 
pulmonary tuberculosis as mentioned before. 
Routine baseline investigations were done in these patients , which include 
renal function test, liver function test , random blood glucose. A chest X- Ray PA 
view was taken in all these patients. 
5 ml of anti-coagulated blood was taken after venipuncture. This blood was 
subjected to automated analyzer counting and peripheral smear examination. 
From results obtained from complete haemogram , these two sets of patients 
namely TB with HIV and TB without HIV were compared with respect to 
haematological profile. 
Our study clearly shows that both HIV and TB affects the adult age group. 
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Among patients belonging to TB with HIV 70 % were in the age group of 25 – 
45 years, whereas it is 86.6% in patients belonging to TB without HIV. 
This is further confirmed by study conducted by Olaniyi J . A , et al ( ref 3 ), in 
Tanzania, in which 74% of patients belong to age group of 25 – 45 years. Hence both 
TB and HIV have great impact in patients of adult age group. 
FIGURE 1 :  age wise distribution ( in percentage) of TB with HIV patients 
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X axis – Age group of the patients; Y axis – percentage of patients in each group 
FIGURE 2 : Age wise distribution ( in percentage)  of TB without HIV patients 
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Regarding the sex distribution between these two sets of patients ,  both HIV 
and TB is more common in male sex . In our study, 83% were males and 16.6% were 
females in patients with TB with HIV , whereas it is 76.6% males and 23.3% females 
in TB without HIV. 
This finding can not be taken as fool proof , as the female patients attending 
the thoracic medicine OP is very less, due to social stigma and taboos. 
Regarding BMI, majority of patients in both the group belong to underweight 
i.e, BMI < 18.5. around 90 % of patients in TB with HIV group and 73.3% of patients 
in TB with out HIV were under weight.  
According to study by Morris , Bird and et.al..the basic pathogenesis for 
cachexia in HIV and TB patients was due to cytokines IL-1 , IL-6 , and TNF – alpha. 
Among the various haematological abnormality noted in these patients , 
anemia , thrombocytopenia , and variation in ESR were very significant, 
ANEMIA : 
In our study anemia was found in both groups. In case of patients of TB with 
HIV 80% had haemoglobin less than 11gm / dl and 66.6% of TB without HIV patients 
had Hb less than 11 gm/dl. Among the anemic patients belonging to TB with HIV 
87.5%  were males and 12.5 % were females. 
In case of anemic patients belonging to TB without HIV , 75% were males and 
25 % were females. 
Our study is well comparable to the study done by Morris, sharma et.al, in 
which anemia was seen in 80% of patients with TB and HIV coinfection. 
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FIGURE ; 3 : Hemoglobin levels in HIV infection/ Immunological AIDS. 
 
 
Our study coincide with that study conducted by SULLIVAN PS in HIV infected males, i.e, 
around 70% of male patients are anemic in the category of TB with HIV. Mostly these patients 
belong to HIV infection or immunological AIDS, which are cases chosen particularly for this 
study. 
 
        Since the HIV patients chosen for this study belong to early stage of HIV 
infection, there is no remarkable changes in WBC counts. According to Murphy M, 
Metcalfe et.al ( ref 8 )., neutropenia occur in late stage of CLINICAL AIDS, whereas 
lymphocytopenia may occur before neutropenia as HIV infection mostly attacks 
lymphocytes. 
In our study also both the group of patients i.e TB with HIV and TB without 
HIV had normal WBC count in 93%.  
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In case of differential count, 23% of TB with HIV patients had 
lymphocytopenia. 
In patients with tuberculosis, there was no significant alteration in terms of 
total WBC counts, and differential counts.12% of patients with Tuberculosis per se 
had lymphocytosis. 
PLATELETS: 
According to a study conducted in 350 pulmonary TB patients, thrombopoeisis 
is seen 33% of patients, 3 % had thrombocytopenia and 64 % had normal to low 
normal level of platelets (Dr.Sharma MD AIIMS, JIMA, 2006) 
In HIV positive patients, according to Sullivan PS, Hanson DL et al (ref 7), 
isolated thrombocytopenia may be early consequences of HIV infection and if CD 4 
count is less than 250, this may increase upto 40 % due to direct toxic effects of HIV 
on the megakaryocytes.  
According to Adrian Mindel et al HIV and haematological problems, 
thrombocytopenia is common in HIV disease and only if persistent, cause bleeding. 
In our study, 63.3% of patients belonging to TB with HIV positive status had 
thrombocytopenia, whereas only 10% of patients had thrombocytopenia among TB 
without HIV status. 
In the contrary, 53.3% of patients had normal platelet counts and 36.6% had 
thrombocytosis in patients with TB per se. 
Among the patients with thrombocytopenia I TB with HIV study group , 
84.2% were males and 15.7% were females. 
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Among patients with thrombocytosis in TB with HIV negative status, 72.7% 
were males and 27.2% were females. 
VARIATION IN PLATELET COUNTS AMONG TUBERCULOSIS 
PATIENTS WITH AND WITHOUT HIV 
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Y axis – No. of patients in the study group 
 
ERYTHROCYTE SEDIMENTATION RATE 
ESR is a marker of ongoing inflammatory reaction. It may be elevated in gross 
situations. The tuberculosis patients had high ESR value compared HIV positive TB 
patients. 
According to the study of KAMALESH SARKAR and co workers, ESR may 
be an indicator for screening of tuberculosis patients for underlying HIV infection, 
particularly in poor resource settings. 
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They had taken 34 patients with TB positive and HIV positive in one group 
and 25 patients with TB without HIV in another group. They have done routine 
investigation which included Total count (TC), Differential count DC), haemoglobin 
(Hb), ESR for both group of patients. 
The data were compared between the two groups. According to the study, there 
was not much difference in basic investigations between these two groups except in 
ESR values. Most tuberculous patients with HIV infection had a much lower ESR 
value compared to the control group. 
               TB with HIV                      Mean value of ESR 38.5 mm/hr 
                                                          Median  value of ESR 30 mm/hr 
              TB without HIV                  Mean value of ESR 142 mm/hr 
                                                           Median value of ESR 108mm/hr. 
In our study, 96.6% of patients belonging to TB without HIV negative status 
had ESR more than 60 mm / hr., in which 73.3% were males and 26.3% were females.  
Only 3.3% of patients in TB with out HIV had ESR less than 60 mm / hr.  
In our study , 83.3% of patients belong to TB with HIV had ESR in the range 
of 0-60 mm/hr. and only 16.6% of patients in this group had ESR in range of 61 – 120 
mm / hr. 
Among these 66.6% of males had ESR less than 60 mm / hr and 16.6% of 
females had ESR less than 6omm / hr. 
Hence p value is 0.001, which is significant, we can conclude that ESR is 
drastically reduced in patents with TB- HIV co-infection rather TB alone. 
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FIGURE 3 : Correlation of ESR with study groups 
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SUMMARY OF HAEMATOLOGICAL CHANGES 
 
Haematological parameter HIV status range median mean ‘p’ value 
Positive 6.4-12.6 9.1 9.2 0.201  
In significant 
Haemoglobin 
( in gm / dl ) 
Negative 6-12.8 9.9 9.76 0.231 
In significant 
Positive 2.2-4.2 3.0 3.1 0.121 
In significant 
RBC 
(in mill /cumm) 
Negative 2.3-4.2 3.3 3.3 0.212 
In significant 
Positive 3400-10000 6500 6538 0.112 
In significant 
WBC 
(in cells/cumm) 
Negative 3600-10950 6500 6696 0.211 
In significant 
Positive 20-120 30 38 0.001 
Significant 
ESR 
(in mm/hr ) 
Negative 60-120 108 102 0.002 
Significant 
Positive 0.4-3.0 1.60 1.54 0.001 
Significant 
Platelets 
( in mill/cumm) 
Negative 1.0-5.6 3.05 3.31 0.002 
Significant 
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SUMMARY 
 
The study “HAEMATOLOGICAL PROFILE OF PULMONARY 
TUBERCULOSIS PATIENTS WITH AND WITHOUT HIV” was done in 60 
patients, with 30 patients in TB with HIV and 30 patients in TB without HIV, who 
attended the department of thoracic medicine and anti retroviral therapy centre, GRH, 
Madurai. 
 
            Pulmonary tuberculosis patients were detected by clinical examination and by 
sputum positivity for AFB, using Ziehl-Nielson technique. Among pulmonary 
tuberculosis patients, HIV was confirmed by both ELISA and WESTERN BLOT 
assay. 
 
After a baseline investigations, complete haemogram was done on these 
patients using automated analyzer and peripheral smear examination. 
 
In our study, 83.3% were males and 16.6 % were females in the TB with HIV 
group. Whereas 76.6% were males and 23.3% were females in the TB without HIV 
group. Hence males dominated in both groups. 
 
In our study, 70% of patients were in the age group of 25 – 45 years in the TB 
with HIV group, whereas 86.6% 0f patients were in age group of 25 – 45 years in the 
TB without HIV. Hence, both the disease predominantly affect adults. 
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In our study, 90 % of patients were underweight with BMI less than 18.5, in 
TB with HIV group, and 73.3% of patients were underweight in TB without HIV 
group. Since both disease causes chronic wasting, co-infection of TB with HIV may 
have deleterious effect in BMI. 
 
In our study, 80 % were anemic in the TB with HIV and 66.6% were anemic in 
TB without HIV group. Among those anemic patients, male patients were more (70 % 
vs 34%) anemic. 
 
In our study, WBC count was not much altered in both the study groups, in 
which more than 65% of patients had normal WBC count in the TB with HIV groups 
and 70% of patients had normal WBC counts in TB without HIV. Since HIV was in 
early stages, the WBC count has not drastically reduced. 
 
          In our   study, 63.3% of patients with TB and HIV had thrombocytopenia, 
whereas only 10% of patients had thrombocytopenia in TB without HIV group. 
Instead, 36.6% of patients had thrombocytosis in the TB without HIV group. 
 
Since isolated thrombocytopenia is a well documented feature in HIV patients, 
and either normal platelet counts or thrombopoeisis occur in pulmonary tuberculosis 
patient per se, the co-infection TB and HIV has drastically reduced the platelet count 
in these patients. 
 
In our study, yet another finding is that, patients with tuberculosis per se have 
increased ESR count, whereas TB-HIV coinfection has drastically reduced the ESR 
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count. Among patients with TB and HIV 83.3% of patients had ESR less than 60 
mm/hr., whereas 96.6% of TB without HIV patients had ESR greater than 60 mm/hr. 
since, ESR is a marker of chronic inflammatory states like TB and HIV is a 
immunosuppressive state, the co-infection of TB with HIV has drastically reduced 
ESR values in these patients. 
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CONCLUSION 
 
I. Both the diseases predominantly affect the male sex. 
II. Both the diseases affect the economically productive age group of the nation, 
namely adults belonging to 25 – 45 years. 
III. Anemia is common in both diseases, but the combination further worsens this 
scenario. 
IV. There is not much reduction in WBC count, as the patients chosen for this 
study belong to either asymptomatic AIDS or immunological AIDS. 
V. The platelet counts are drastically reduced even in asymptomatic AIDS 
patients, hence this parameter can be used as marker of early HIV infection 
among the pulmonary tuberculosis patients. 
VI. ESR values are drastically reduced in TB patients with HIV, rather TB patients 
per se. hence, an ESR less than 60 mm / hr in pulmonary tuberculosis patients 
should arouse a suspicion of underlying immunocompromised state. 
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LIMITATIONS OF THE STUDY  
 
 Since the study group contained 60 patients, selection bias have been 
confounded, with respect to sex distribution, Hence a large study group is needed to 
overcome this bias.     
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GLOSSARY 
 
1. BMI        :    body mass index 
2. Hb           : haemoglobin 
3. TC      :     total count 
4. P              :     polymorphs 
5. L             :     lymphocyte 
6. E             :      eosinophil 
7. M         :    monocyte 
8. ESR           :    Erythrocyte sedimentation rate 
9. HIV   :    Human Immunodeficiency Virus 
10. AIDS          :     Acquired ImmunoDeficiency Disease 
11. TB               :      tuberculosis 
12. RNTCP  :    revised national tuberculosis control program 
13. NACO  :    national AIDS control society 
14. ELISA  : enzyme linked immunosorbent assay. 
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PROFORMA 
Name:                                                             Age:                      Sex :                                                            
IP/OP  No :                                                      Occupation : 
Marital status:                                                  WHO stage : 
Educational status : 
Clinical status : 
           Cough with expectoration for > 3 weeks :    Y/N 
           Evening rise of temperature                     :   Y /N 
           Loss of appetite ( anorexia )                     :   Y/N 
           Significant loss of weight                         :    Y/N 
Past History : 
           Diabetes :    Y/N                      Hypertension :  Y/N 
           IHD :    Y/N                      Pulmonary TB:  Y/N        
Drug History :    Y/N               Anti retroviral drugs ( For HIV ) 
                                                 Anti  Tuberculosis Drugs ( for Pulmonary TB ) 
Personal History :  
            Smoking:    Y/N            Duration:                      Packs/ Day 
            Alcohol   :    Y/N          Duration: 
             Diet        :    Veg/ Non veg 
Family History ; 
             Diabetes :     Y/N 
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PERSONAL HISTORY : 
              Exposure to STD        :  Y/N 
              H/o sexual promiscuity :  Y/N  
  Examination :                                                                  
        Height : in meters              Weight : in Kilogram                        BMI  ;   
Vital signs 
         (a) Pulse rate                                      (b) Respiratory rate 
         (c) Blood pressure 
Systems : 
Cardio vascular status                        
Respiratory status 
Neurological status                             
Investigations:  
Urine  albumin   : 
               Sugar      : 
               Deposit   :  
Blood Urea       : 
Ser Creatinine   : 
Liver Function Test: 
Complete haemogram ( incl.peripheral smear study ); 
CD4  Count / ul   : 
      Percentage     :  
HIV  RNA copies:   
Chest X-ray (PA view ): 
    S.NO    IP NO    AGE    SEX WEIGHT HEIGHT    BMI      Hb     RBC      TC       P       L       E       M     ESR PLATLET
in years     in kg in cm     in gm in million in mm/hr cells/cmm
1 29837 55      M 35 154 14.76 9 3 9200 56 42 2 0 42 1,60,000
2 23234 55      M 36 159 14.28 7.2 2.5 7600 52 40 8 0 24 80,000
3 28365 65      M 50 172 16.9 12.6 4.2 6550 52 44 4 0 26 1,80,000
4 23432 45      M 37 166 13.5 11.2 4 7300 60 36 4 0 28 2,50,000
5 29832 47      M 40 161 16.4 5.5 2 3400 79 20 1 0 36 70,000
6 23273 19       F 49 168 17.4 11.4 3.8 6000 58 39 3 0 48 2,00,000
7 26734 52      M 41 158 16.4 6.4 2.2 5850 57 43 0 0 58 60,000
8 28934 46      M 51 170 17.6 7 2.4 3600 70 26 4 0 60 1,00,000
9 23273 26      M 37 166 13.6 7.2 2.5 5900 52 46 2 0 24 90,000
10 29387 35      M 34 155 14.2 9.6 3.2 6300 60 33 7 0 30 1,00,000
11 32232 30        F 35 155 14.6 10.6 3.5 7400 67 26 2 5 32 1,80,000
12 23463 65      M 41 158 16.5 12.6 4.2 6550 52 44 4 0 22 2,80,000
13 30893 25      M 51 170 17.6 7.2 2.5 3600 63 36 1 0 62 50,000
14 30897 40      M 59 160 23 8 2.7 8000 62 36 0 0 74 50,000
15 30987 45        F 36 165 14 8.6 2.9 7050 62 36 2 2 22 2,00,000
MASTER CHART - TB with HIV
    S.NO    IP NO    AGE    SEX WEIGHT HEIGHT    BMI      Hb     RBC      TC       P       L       E       M     ESR PLATLET
16 31898 32      M 36 156 14.8 8.9 2.9 7600 62 33 3 0 20 3,00,000
17 26343 25        F 42 160 16.4 7.6 2.6 6400 62 33 5 2 28 1,00,000
18 27354 25      M 46 167 16.54 10.2 3.4 3400 56 42 2 0 52 1,20,000
19 27365 33        F 44 163 16.6 12.8 4.3 7400 60 40 0 0 30 1,60,000
20 28376 36      M 55 158 22 8.8 3 5750 56 40 2 2 44 3,00,000
21 29833 32      M 40 167 14.4 8.4 2.9 6350 56 40 2 2 28 40,000
22 25436 35      M 44 162 16.7 9.4 3.1 6400 64 34 2 0 102 2,80,000
23 28734 21      M  28 145 13.4 10.2 3.4 7400 64 34 2 0 26 1,60,000
24 28372 33      M  54 164 20.14 9 3 6450 46 50 2 2 30 2,40,000
25 29374 55      M 42 162 16.03 9.8 3.3 7200 56 42 2 0 106 1,60,000
26 22323 29      M 31 151 13.59 10.7 3.7 8600 60 40 0 0 48 2,20,000
27 29323 35      M 45 160 17.5 12.6 4.2 10000 56 40 0 4 28 1,70,000
28 24383 32      M 31 154 13 8.2 2.8 7400 42 56 0 2 22 90,000
29 21928 29      M 45 160 17.5 7.9 2.7 5300 56 36 6 2 28 1,00,000
30 30918 33      M 32 157 13 7.1 2.4 6800 46 52 2 0 120 80,000
S.NO  I.P NO AGE SEX WEIGHT HEIGHT BMI Hb RBC TC P L E M ESR PLATELET
in years   in kg in cm   in gm/dl mill/cumm cells/cmm mill/cumm
1 29834 33 M 43 156 17.6 8.9 3.1 8350 80 18 2 0 88 4.9
2 24394 30 F 41 170 14.2 12.2 4.2 6100 62 36 2 0 80 5.6
3 29387 35 M 47 168 16.6 11.8 4.1 7200 62 36 2 0 68 4.7
4 23453 27 M 40 159 15.8 11.8 4 6300 60 34 3 3 76 2
5 28374 30 F 41 170 14.2 10.9 3.6 6750 56 41 3 0 116 2.7
6 24355 38 M 35 155 14.6 8.8 3 8500 68 30 2 0 96 4.9
7 39887 40 M 44 153 18.8 8.6 3 8000 62 36 0 2 120 3.5
8 32433 35 M 41 158 16.5 9.4 2.6 10950 60 38 2 0 116 3.6
9 32662 50 M 44 157 14.9 11.6 3.8 5000 65 35 0 0 108 3.4
10 37726 42 M 59 147 27.3 10.4 3.4 5200 63 34 0 3 92 2.2
11 38463 30 F 35 155 14.6 10.6 3.5 7400 67 26 2 5 106 2.7
12 42234 47 F 47 168 16.7 12.6 4.2 6800 58 38 4 0 78 3.1
13 36253 35 F 58 157 23.6 7.4 2.6 10950 60 38 2 0 106 4.8
14 23432 45 F 41 156 16.5 7.2 2.6 3600 63 36 1 0 120 2
15 27873 42 M 41 151 16.3 12.6 4.2 6000 52 46 2 0 96 4.8
MASTER CHART - TB without HIV
16 28837 29 M 36 170 12.5 12.8 2.6 8100 52 46 2 0 92 5.1
17 37726 33 M 39 161 15 11.2 3.7 7650 48 45 2 0 116 1.6
18 37776 30 M 34 151 14.9 10 3.3 7450 48 50 2 0 98 1.7
19 34283 31 M 43 150 19.1 10.6 3.5 5400 57 40 3 0 60 5.4
20 32493 42 M 39 158 15.6 8.8 3 6400 40 56 1 3 104 2.8
21 34263 52 F 38 160 14.8 9.8 3.3 6700 56 44 0 0 98 4.8
22 39263 35 M 49 168 18.4 7.6 2.7 3700 46 52 2 0 86 2
23 24363 38 M 29 151 14.1 11.6 3.8 6400 55 41 4 0 84 2.2
24 29387 32 M 35 165 14.3 9.8 3.4 3700 48 50 2 0 92 2.8
25 26372 30 M 43 158 17.2 7.2 2.6 6500 62 35 3 0 80 1
26 26632 50 M 58 149 26.1 6 2.3 6400 52 44 2 0 96 1.2
27 28763 37 M 64 167 23 9.6 3.2 5600 51 48 1 0 75 3
28 25435 38 M 45 154 18.9 11.4 3.8 8500 52 48 0 0 108 4.8
29 25377 45 M 67 163 17.7 9.2 3.1 6500 46 52 2 0 112 5.2
30 27366 36 M 52 154 21.9 6 2.3 4500 48 52 0 0 114 1
